Published in final edited form as:

Bioorg Med Chem Lett. 2008 December 1; 18(23): 6119–6121. doi:10.1016/j.bmcl.2008.10.024.

In Situ Blood-Brain Barrier Permeability of a C-10 Paclitaxel Carbamate

Carlo Ballatore^{a,b}, Bin Zhang^a, John Q. Trojanowski^a, Virginia M.-Y. Lee^a, and Amos B. Smith III^b

^aCenter for Neurodegenerative Diseases Research, Institute on Aging, University of Pennsylvania, 3600 Spruce Street, Philadelphia, PA 19104-6323

^bDepartment of Chemistry, University of Pennsylvania, 231 South 34th St., Philadelphia, PA 19104-6323

Abstract

We report the synthesis and blood-brain barrier (BBB) permeability of ¹⁴C-CNDR-29, a paclitaxel C-10 carbamate derivative shown to be devoid of P-glycoprotein (Pgp)-interactions, in an *in situ* mouse brain perfusion model, in comparison with ¹⁴C-paclitaxel. The results presented reveal a 3–4 fold higher BBB-permeability for the C-10 modified taxane compared to paclitaxel. These results support the notion that circumvention of Pgp-mediated efflux can lead to higher BBB-permeability. Further studies however are needed to evaluate the therapeutic potential of the C-10 carbamates paclitaxel derivatives for the treatment of CNS diseases.

Over the past several years, there has been growing interest in the development of brain-penetrant microtubule stabilizing (MT)-agents for the treatment of different central nervous system (CNS) conditions, including cancer as well as non-proliferative diseases such as Alzheimer's disease (AD) and related disorders.¹ Among the various classes of MT-stabilizing natural products, taxanes have been arguably one of the most intensely studied.

Indeed, paclitaxel² (Fig. 1), the first chemotherapeutic MT-stabilizing agent to receive FDA approval for the treatment of cancer, was found to be a potential clinical candidate for other disorders, including neurodegenerative diseases.³ However, the issue of limited brain uptake due to poor blood-brain barrier (BBB)-permeability prevented further development of this compound for CNS indications. Paclitaxel, as well as several related compounds, is known to be a good substrate for the ATP-binding cassette (ABC) active transporter P-glycoprotein (Pgp),⁴ which is highly expressed in the kidneys, liver, intestine and the BBB.⁵ Previous studies^{6,7} have demonstrated that Pgp-knockout mice exhibit higher paclitaxel cerebral-uptake compared to wild type animals and that pharmacological modulation of Pgp in wild type mice can increase paclitaxel brain levels by 3–6 fold compared to animals non-treated with Pgp-modulators. Furthermore, unlike control animals, when Pgp-knockout mice or wild type mice treated with Pgp-inhibitors were implanted with a tumor in the brain, peripheral administration of paclitaxel was found to produce significant anti-neoplastic effects. Taken together, these findings highlight the importance of Pgp in limiting paclitaxel's entry in the CNS, and suggest that circumvention of Pgp-mediated efflux can produce therapeutically relevant paclitaxel brain levels.^{6,8} However, since Pgp-function comprises an important defense mechanism,

Correspondence to: Carlo Ballatore.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

protecting the CNS from toxic substances, ideal candidate compounds for brain diseases should be able to reach therapeutically effective brain-concentrations without causing a significant disruption in Pgp-function. This is particularly important in the context of chronic neurodegenerative diseases, where lack of Pgp-function, and/or other BBB-dysfunctions, have been clearly linked to the pathology of these diseases.^{9,10}

Importantly, recent studies have shown that selected chemical modifications at the C-10 position of taxanes can result in analogues that are neither substrates nor inhibitors of Pgp.^{11,12} These compounds are typified by the C-10 succinimidyl ester TX-67 (Fig. 1),¹³ which notably was found to have an apparent permeability coefficient 6–10 times higher than paclitaxel, in a rat brain perfusion model.¹¹ Other examples of C-10 modified taxanes lacking Pgp-interactions include a series of C-10 carbamates (e.g., CNDR-3 and CNDR-29, Fig. 1) which were found to be comparatively more stable than C-10 esters like TX-67, and therefore potentially more desirable for further clinical development.¹² Preliminary SAR for the C-10 carbamate series suggested that efficient circumvention of Pgp-mediated efflux *in vitro* could generally be achieved by derivatives bearing a polar moiety, typically a carboxylic acid moiety, at the C-7 or C-10 position. Interestingly, among the C-10 carbamates found to be devoid of Pgp interactions, CNDR-29 was the only example that lacked the carboxylic acid residue. This relatively more lipophilic compound was found to be more cell-permeable than the corresponding carboxylic acid containing analogues, as suggested by cell-cytotoxicity studies.¹² Thus, because of the more favorable combination of lipophilicity and lack of Pgp-interactions, CNDR-29 was selected for BBB-permeability studies in a mouse brain perfusion model. Towards this end [¹⁴C]-labeled CNDR-29 was prepared and tested in comparison with [¹⁴C]-paclitaxel.

[¹⁴C]-CNDR-29 was prepared by reacting an appropriately protected paclitaxel-10-deacetyl-10-carbonyl-N-methylimidazol-inium iodide salt **A**¹⁴ with [1,2-¹⁴C]-ethanolamine (5–10 mCi/mmol), to furnish carbamate **B**, which was directly treated with HF/Py obtaining [¹⁴C]-CNDR-29 (8.5 mCi/mmol; Figure 2).¹⁵ The brain perfusion experiment¹⁶ was conducted in triplicate by infusing 0.1 µCi of the test compound (or [¹⁴C]-paclitaxel), in 500 µl of buffer, into the carotid artery of an appropriately prepared mouse over a 60 seconds time period. Following the infusion, the vasculature was washed for an additional 60 seconds with buffer containing non-radiolabeled compound and finally the animal was sacrificed and the brain collected for quantification of radioactivity in a scintillation counter. A brain perfusion experiment was also conducted with [¹⁴C]-sucrose to verify the physical integrity of the BBB.

The results, summarized in Figure 3, reveal that the total counts observed in brain samples of [¹⁴C]-CNDR-29-treated mice was approximately 3–4 times higher than that found in the corresponding paclitaxel-treated animals, demonstrating that CNDR-29 exhibits higher BBB-permeability than paclitaxel, and thus suggesting that CNDR-29 may be able to reach comparatively higher brain levels than paclitaxel, after peripheral administration. It should be noted, however, that brain perfusion models are relatively controlled experimental systems that do not consider other potentially limiting factors such as metabolism and plasma protein binding, which may greatly influence the overall brain uptake. Thus, although these results clearly suggest a higher permeability for CNDR-29, further studies are needed to evaluate whether the observed relative increase of 3–4 fold in BBB-permeability in the *in situ* mouse brain perfusion model may translate into therapeutically useful brain concentrations after peripheral administration. Nonetheless it is interesting to note that, bearing in mind the experimental differences, these brain perfusion data appear to be in agreement with reports that co-administration (i.p.) of paclitaxel with a range of Pgp-modulators produce a relative increase of 3–6 times in paclitaxel mouse-brain concentrations.^{6,8} These results are also consistent with the notion that circumvention of Pgp-mediated efflux can lead to higher BBB-permeability. Finally, it should be noted that the prototype compound TX-67, under similar

brain perfusion experimental conditions, was reported to have an even more pronounced relative enhancement in BBB-permeability (6–10 fold) compared to paclitaxel. The relatively higher BBB-permeability of TX-67 may support the hypothesis of the involvement of an active transport mechanism (e.g., monocarboxylic acid transporters).¹¹ To evaluate this possibility, and in order to select the most plausible candidate compound(s) for efficacy studies in a transgenic animal model of neurodegenerative tauopathies, a comparative evaluation in mouse PK models of C-10 modified paclitaxel analogues, including TX-67, as well as other MT-stabilizing agents from different classes of natural products is ongoing in our laboratories.

Acknowledgements

Financial support for this work was provided by the NIH (U01 AG029213). We thank Professor Donna Huryn and Dr. Hugo Geerts for helpful discussions.

References

1. Trojanowski JQ, Smith AB III, Huryn D, Lee VM-Y. *Expert Opin. Pharmacother* 2005;6:683–686. [PubMed: 15934894]
2. Rowinsky EK, Donehower RC. *N. Engl. J. Med* 1995;332:1004–1014. [PubMed: 7885406]
3. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, Lee EB, Xie SX, Joyce S, Li C, Toleikis PM, Lee VM-Y, Trojanowski JQ. *Proc. Natl. Acad. Sci. U. S. A* 2005;102:227–231. [PubMed: 15615853]
4. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O. *Proc. Natl. Acad. Sci. U. S. A* 1997;94:2031–2035. [PubMed: 9050899]
5. Girardin F. *Dialogues Clin. Neurosci* 2006;8:311–321. [PubMed: 17117613]
6. Kemper EM, van Zandbergen AE, Cleypool C, Mos HA, Boogerd W, Beijnen JH, van Tellingen O. *Clin. Cancer Res* 2003;9:2849–2855. [PubMed: 12855665]
7. Gallo JM, Li S, Guo P, Reed K, Ma J. *Cancer Res* 2003;63:5114–5117. [PubMed: 12941842]
8. Fricker G, Miller DS. *Pharmacology* 2004;70:169–176. [PubMed: 15001817]
9. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnicka-Worms D, Holtzman DM. *J. Clin. Invest* 2005;115:3285–3290. [PubMed: 16239972]
10. Zlokovic BV. *Neuron* 2008;57:178–201. [PubMed: 18215617]
11. Rice A, Liu Y, Michaelis ML, Himes RH, Georg GI, Audus KL. *J. Med. Chem* 2005;48:832–838. [PubMed: 15689167]
12. Ballatore C, Hyde E, Deiches RF, Lee VM-Y, Trojanowski JQ, Huryn D, Smith AB III. *Bioorg. Med. Chem. Lett* 2007;17:3642–3646. [PubMed: 17485207]
13. Yanbin Liu F, Ali SM, Boge TC, Georg GI, Victory S, Zygmunt J, Marquez RT, Himes RH. *Comb. Chem. High Throughput Screen* 2002;5:39–48. [PubMed: 11860338]
14. Ballatore C, Aspland SE, Castillo R, Desharnais J, Eustaquio T, Sun C, Castellino AJ, Smith AB III. *Bioorg. Med. Chem. Lett* 2005;15:2477–2480. [PubMed: 15863300]
15. Detailed experimental procedure for the synthesis of [¹⁴C]-CNDR-29: To a previously prepared imidazolinium iodide salt **A** (14.4 mg, 0.011 mmol) in a 20 mL scintillation vial (screw cap) fitted with a magnetic stir bar, an addition of [1,2-¹⁴C]-ethanolamine hydrochloride (250 µCi; 5–10 mCi/mmol; 0.0333 mmol in 2.5 mL of ethyl alcohol; Moravek Biochemicals and Radiochemicals) is made using a disposable 5 mL syringe, followed by an addition of diisopropylethyl amine (DIEA; 9.2 µL; ~0.066 mmol). The reaction vessel is then capped and stirred for 30 minutes at room temperature to give compound **B**, which is directly used for the next step without any purification or work-up. Thus, the crude reaction mixture is diluted with 0.5 mL of pyridine, cooled to 0°C, and finally added with 100 µL of HF/pyridine. The reaction mixture is then allowed to stir for 16 h (overnight) allowing the temperature to rise to room temperature. After 18 hours the reaction is quenched by addition of 100 µL of a saturated solution of CuSO₄, then the mixture is concentrated via a stream of nitrogen (3–4 hours). The residue is re-dissolved in ~5 mL of ethyl acetate and the resulting mixture is washed with 1 mL of a saturated solution of CuSO₄ directly in the same scintillation vial used for the synthesis.

The top organic layer is then collected with a Pasteur and transferred into a new scintillation vial. After removal of the volatiles via a stream of nitrogen the residue is re-dissolved in the minimal amount of dichloromethane/methyl alcohol 9:1 (ca. 100 μ L). Finally, the compound is purified by preparative TLC (dichloromethane/methyl alcohol, 9:1) obtaining the desired compound (4.2 mg; 42% yield; 8.5 mCi/mmol).

16. The brain perfusion experiment was adapted from previously described procedures:¹⁷ brain perfusion experiments were conducted using B6C3 mice. A 0.5 inch incision was made in the skin of anesthetized animals in order to expose the carotid triangle. After separation of superficial structures, such as thyroid and salivary glands, non-blood vessel soft tissue and fat, the carotid sheath was exposed and carefully dissected to expose the internal and external branches of the carotid artery. A single suture was then tied to the external carotid branch, while two additional sutures were set loosely in the proximal and distal region of the common carotid artery respectively. The proximal ligature was then gently tighten and the distal portion of the artery was clamped off. One end of a P10 tubing was then inserted near the proximal ligature to a depth of ~2 mm, while the other end was connected to a 1 mL syringe filled with saline. The distal clamp was then released and a small amount of saline was injected into the internal branch of the carotid artery to check for signs of leaking or bleeding. The P10 tubing was then connected to a perfusion pump with 1 mL syringe filled with the test compound. The heart was then exposed, stopped and the right atrium cut to allow blood outflow and finally infusion of the test compound was made at a 0.5 mL/minute for a total volume of 0.5 mL. An isotonic solution (500uL saline with 100IU heparin) containing non-radiolabeled test compound was then infused at 0.5 mL/minute to rinse the vasculature and then the brain was immediately collected and cut in small pieces which were dissolved in 5 mL of Solvable overnight at 60 °C. The samples were then added with 0.1 mL of 30% H₂O₂ and incubation continued for an additional 30 minutes until discoloration. A 1 mL of brain sample was then added with 5 mL of Ultima Gold and the radioactivity measured in a scintillation counter.
17. Audus, K.; Rose, JM.; Wang, W.; Borchardt, RT. Brain microvessel endothelial cell culture systems. In: Pardridge, WM., editor. *An Introduction to the Blood-Brain Barrier: Methodology and Biology*. Cambridge: Cambridge University; 1998. p. 86-93.

Figure 1. Paclitaxel and representative structures of C-10 modified derivatives known to be devoid of Pgp-interactions.

Figure 2.
Synthesis of [^{14}C]-CNDR-29. [^{14}C]-labels are indicated with an asterix

Figure 3.
CPMs in [^{14}C]-CNDR-29 and [^{14}C]-paclitaxel infused mice brain